Table 3.
Expression of BAFF/BAFF-R, NF-κB Proteins, and EBV in Patients with DLBCL
| Lymphoma type | Origin | No. of patients | BAFF | BAFF-R | p52 | p50 | EBV | LMP1 |
|---|---|---|---|---|---|---|---|---|
| IC | GC | 12 | 11 of 12 | 6 of 12 | 5 of 12 | 3 of 12 | 0 | ND |
| IC | NGC | 18 | 17 of 18 | 5 of 18 | 0 of 18 | 3 of 18 | 2/18 | 2/2 |
| PTLD | NGC | 19 | 17 of 19 | 1 of 19⁎ | 12 of 19⁎ | 7 of 17 | 10 of 19 | 9 of 10 |
| PTLD | ND | 2 | 2 of 2 | 0 of 2 | 2 of 2 | 1 of 2 | 2 of 2 | 1 of 2 |
GC, germinal center; IC, immunocompetent; EBV, Epstein-Barr virus; LMP1, latent membrane protein 1; ND, not determined; NGC, non–germinal center; p50 and p52 positive staining, nuclear localization (>10%); PTLD, post-transplantation lymphoproliferative disorders.
⁎
Statistically significant: P < 2.10−4 for p52, P < 0.008 for BAFF-R.